会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
    • 26,27同系的20-EPI-2-亚烷基-19-去甲维生素D化合物
    • US06392071B1
    • 2002-05-21
    • US09540686
    • 2000-03-31
    • Hector F. DeLucaRafal R. Sicinski
    • Hector F. DeLucaRafal R. Sicinski
    • C07C40100
    • C07C401/00C07F7/1804Y02P20/55
    • This invention provides a novel class of vitamin D related compounds, namely, the 2-alkylidene-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or when taken together represent the group —(CH2)x— where x is an integer from 2 to 5, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 2-substituted compounds are characterized by relatively high intestinal calcium transport activity and relatively high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.
    • 本发明提供了一类维生素D相关化合物,即2-亚烷基-19-去甲维生素D衍生物,以及它们的化学合成的一般方法。 这些化合物具有下式:其中可以相同或不同的Y1和Y2各自选自氢和羟基保护基,各自选择可以相同或不同的R6和R8 从氢,烷基,羟基烷基和氟烷基,或当它们一起表示 - (CH 2)x - 基团,其中x是2至5的整数,并且其中基团R表示维生素D型化合物已知的任何典型侧链 。 这些2-取代的化合物的特征在于相对较高的肠钙运输活性和相对高的骨钙动员活性,导致用于治疗需要骨形成,特别是低骨转换性骨质疏松症的疾病的新型治疗剂。 这些化合物在阻止未分化细胞的增殖并诱导其分化为单核细胞方面也表现出显着的活性,因此证明其用作抗癌剂并用于治疗诸如牛皮癣的疾病。
    • 2. 发明授权
    • Vitamin D analogs and methods of preparing these compounds
    • 维生素D类似物和制备这些化合物的方法
    • US06288249B1
    • 2001-09-11
    • US09180136
    • 1999-06-16
    • Sebastianus J. HalkesJan Paul Van De VeldeSilvia KanzlerWolfgang Reischl
    • Sebastianus J. HalkesJan Paul Van De VeldeSilvia KanzlerWolfgang Reischl
    • C07C40100
    • C07C33/38C07C2602/08
    • The invention relates to vitamin D analogs of general formula (I) wherein: R1 is a hydrogen atom or a substituent selected from the group consisting of hydroxy, CH2OH, CH2CH2OH, CH2CH2CH2OH, OCH3, OCH2OH, OCH2CH2OH and OCH2CH2CH2OH; R2 is a hydrogen atom or a substituent selected from the group consisting of OCH3, OCH2OH, CHm(CH2OH)n(CH2CH2OH)p, (CH2)qOH and O(CH2)rOH; wherein: m is 0 or 1, p, q and n are 0-3, r is 1-3 and m+n+p=3; with the proviso that R1 and/or R2 contain at least one OH group; R3 is a straight or branched, saturated or unsaturated aliphatic hydrocarbon of 6-13 C atoms which may be substituted with one or more substituents from the group hydroxy or fluoro. The invention further relates to methods of preparing these compounds, a pharmaceutical composition containing these compounds and to their use in pharmacotherapy and cosmetics.
    • 本发明涉及通式(I)的维生素D类似物,其中:R 1是氢原子或选自羟基,CH 2 OH,CH 2 CH 2 OH,CH 2 CH 2 CH 2 OH,OCH 3,OCH 2 OH,OCH 2 CH 2 OH和OCH 2 CH 2 CH 2 OH的取代基; R2是氢原子或选自OCH3,OCH2OH,CHm(CH2OH)n(CH2CH2OH)p,(CH2)qOH和O(CH2)rOH的取代基; 其中:m为0或1,p,q和n为0-3,r为1-3,m + n + p = 3; 条件是R1和/或R2含有至少一个OH基团; R3是6-13个碳原子的直链或支链饱和或不饱和脂族烃基,其可被一个或多个羟基或氟取代基取代。 本发明还涉及制备这些化合物的方法,含有这些化合物的药物组合物及其在药物治疗和化妆品中的用途。
    • 4. 发明授权
    • Intermediates for vitamin D and processes for the preparation thereof
    • 维生素D的中间体及其制备方法
    • US06753435B1
    • 2004-06-22
    • US10239778
    • 2002-09-25
    • Masahiro KogaToru Minoshima
    • Masahiro KogaToru Minoshima
    • C07C40100
    • C07C401/00C07C309/65C07C2601/14C07C2601/16C07C2602/24C07F7/1804C07F7/1892
    • An object of the present invention is to provide intermediates for the synthesis of 1&agr;-hydroxyvitamin D derivatives useful as drugs and processes for the preparation thereof. Namely, the present invention is a process for the preparation of a compound represented by the formula (2), which comprises reacting a compound represented by the formula (1) with a compound represented by the formula (4) in the presence of a palladium catalyst, a process for the preparation of a compound represented by the formula (3), which comprises further catalytically reducing the resulting compound represented by the formula (2) in the presence of a Lindlar catalyst and hydrogen gas and heating the obtained product and a process for the preparation of a compound represented by the formula (5), which comprises further oxidizing the resulting compound represented by the formula (3) with an oxidizing agent and the compounds represented by the formulae (1) to (3):
    • 本发明的目的是提供用作合成作为药物的1α-羟基维生素D衍生物的中间体及其制备方法。本发明是制备式(2)表示的化合物的方法, 其包括在钯催化剂存在下使式(1)表示的化合物与式(4)表示的化合物反应,制备由式(3)表示的化合物的方法,该方法还包括 在Lindlar催化剂和氢气的存在下催化还原由式(2)表示的化合物,并加热得到的产物和制备由式(5)表示的化合物的方法,该方法包括进一步氧化所得 由式(3)表示的化合物与氧化剂和由式(1)至(3)表示的化合物:
    • 7. 发明授权
    • Crystals of vitamin D derivatives and process for the preparation thereof
    • 维生素D衍生物晶体及其制备方法
    • US06448421B1
    • 2002-09-10
    • US09202144
    • 1998-12-09
    • Tsuyoshi Yamauchi
    • Tsuyoshi Yamauchi
    • C07C40100
    • C07J9/00C07C401/00C07J71/001
    • The present invention provides crystals of the compound represented by formula (I): crystals of a vitamin D derivative which are obtained by purifying a crude or preliminarily purified product of the vitamin D derivative through a reverse phase chromatography and then crystallizing the purified derivative from an organic solvent; novel compounds which are formed during the synthesis of a vitamin D derivative as by-product; and a method for purifying a vitamin D derivative or the precursor thereof. The method of the present invention makes it possible to supply a highly purified vitamin D derivative, especially ED-71, in bulk and steadily.
    • 本发明提供由式(I)表示的化合物的晶体:维生素D衍生物的结晶,其通过反相色谱法纯化维生素D衍生物的粗产物或预纯化产物,然后将纯化的衍生物从 有机溶剂; 在合成维生素D衍生物作为副产物期间形成的新化合物; 以及维生素D衍生物或其前体的纯化方法。 本发明的方法使得可以大量和稳定地供应高度纯化的维生素D衍生物,特别是ED-71。